Amoxycillin and Clavulanic Acid 500/125 (Apo) is a medicine containing the active ingredient(s) amoxicillin + clavulanic acid. On this page you will find out more about Amoxycillin and Clavulanic Acid 500/125 (Apo), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: amoxicillin + clavulanic acid
Information for medicine and pack size:
Amoxycillin and Clavulanic Acid 500/125 (Apo) film-coated tablet, 10
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Amoxycillin and clavulanic acid tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms(see Microbiology): - Urinary tract infections (uncomplicated and complicated). - Lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. - Upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. - Skin and skin structure infections. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to APO-Amoxycillin and Clavulanic acid 500 /125 tablet.s. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in Microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to APO-Amoxycillin and Clavulanic acid 500 /125 tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.
Table of characteristics
White convex capsule shaped film coated tablet
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
10 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Moisture|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 January 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.